Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal

Cancer Core Europe consortium

doi:10.1038/s41591-020-0969-2

Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal

Cancer Core Europe consortium

Research related

Onderzoeksoutput: Bijdrage aan tijdschrift › Brief › peer review

70 Citaten (Scopus)

Originele taal-2	Engels
Pagina's (van-tot)	992-994
Aantal pagina's	3
Tijdschrift	Nature Medicine
Volume	26
Nummer van het tijdschrift	7
DOI's	https://doi.org/10.1038/s41591-020-0969-2
Status	Gepubliceerd - 1 jul 2020

Toegang tot document

10.1038/s41591-020-0969-2

Citeer dit

@article{f57b8062dcd944e88db7a33a07831641,

title = "Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal",

author = "\{Cancer Core Europe consortium\} and David Tamborero and Rodrigo Dienstmann and Rachid, \{Maan Haj\} and Jorrit Boekel and Richard Baird and Irene Bra{\~n}a and \{De Petris\}, Luigi and Jeffrey Yachnin and Christophe Massard and Opdam, \{Frans L.\} and Richard Schlenk and Claudio Vernieri and Elena Garralda and Michele Masucci and Xenia Villalobos and Elena Chavarria and Shubha Anand and Anal{\'i}a Azaro and Danny Baars and Svetlana Bajalica-Lagercrantz and Judith Balma{\~n}a and Jonas Bergh and Mariska Bierkens and Lennart Blomqvist and Doherty, \{Gary J.\} and Arnauld Forest and Valentina Fornerone and Funingana, \{Ionut Gabriel\} and Paola Gabaldi and Johan Hartman and Peter Horak and Claes Karlsson and Mary Kasanicki and Simon Kreutzfeldt and Rolf Lewensohn and Johan Lindberg and Carlos Lopez and Andreas Lundqvist and Patricia Martin-Romano and Martin, \{Jose Ezequiel\} and Gerrit Meijer and Susana Mu{\~n}oz and Camus, \{Maud Ngo\} and Claudio Nicotra and Paolo Nuciforo and Petra Oberrauch and P{\"a}ivi {\"O}stling and Alejandro Piris-Gim{\'e}nez and Elena Provenzano and Alexander Eggermont",

note = "Funding Information: Orion Pharma and speaker activities for Bristol Myers Squibb; reports travel grants from AstraZeneca and Merck Serono; and is a principal investigator of clinical trials for AstraZeneca, Bristol Myers Squibb, Celgene, Gliknik, GlaxoSmithKline, Janssen, Kura, Merck, Sharp \& Dohme, Novartis, Orion Pharma, Pfizer, Shattuck, Northern Biologics, Rakutan Aspirian and Nanobiotics. C. M. reports consultant and/or advisory fees from Amgen, Astellas, Astra Zeneca, Bayer, BeiGene, Bristol Myers Squibb, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, Merck, Sharp \& Dohme, Novartis, Pfizer, Roche, Sanofi, Orion; and is a principal or sub-investigator of clinical trials for Abbvie, Aduro, Agios, Amgen, Argen-x, Astex, AstraZeneca, Aveopharmaceuticals, Bayer, Beigene, Blueprint, Bristol Myers Squibb, Boeringer Ingelheim, Celgene, Chugai, Clovis, Daiichi Sankyo, Debiopharm, Eisai, Eos, Exelixis, Forma, Gamamabs, Genentech, Gortec, GlaxoSmithKline, H3 biomedicine, Incyte, Innate Pharma, Janssen, Kura Oncology, Kyowa, Lilly, Loxo, Lysarc, Lytix Biopharma, Medimmune, Menarini, Merus, Merck, Sharp \& Dohme, Nanobiotix, Nektar Therapeutics, Novartis, Octimet, Oncoethix, Oncopeptides, Orion, Pfizer, Pharmamar, Pierre Fabre, Roche, Sanofi, Servier, Sierra Oncology, Taiho, Takeda, Tesaro and Xencor. R. S. reports research funding from Pfizer, AstraZeneca, PharmaMar, Roche and Daiichi Sankyo; speaker honoraria from Pfizer, Daiichi Sankyo and Novartis; and participation in advisory boards at Pfizer, Daiichi Sankyo and Novartis. E. G. reports consultant honoraria from Roche/Genentech, F. Hoffmann La Roche, Ellipses Pharma, Neomed Therapeutics, Boehringer Ingelheim–Janssen Global Services, AstraZeneca, SeaGen, TFS–Alkermes; reports research for Novartis/Roche; is a principal or sub-investigator of clinical trials for Principia Biopharma, Lilly, Novartis Farmac{\'e}utica, Genentech, Loxo Oncology, F. Hoffmann La Roche, Symphogen, Merck, Sharp \& Dohme de Espa{\~n}a, Incyte Biosciences International, Pharma Mar, Kura Oncology, Macrogenics, Glycotope, Pierre Fabre Medicament, Cellestia Biotech, Menarini Ricerche Spa, Blueprint Medicines, Beigene Usa, Sierra Oncology and Genmab; reports travel grants from Bristol-Mayers Squibb, Merck Sharp \& Dohme, Menarini, Glycotope; and is on the speakers bureau for Bristol-Mayers Squibb, Merck Sharp \& Dohme, Roche and ThermoFisher. S. F. reports a consulting or advisory role, having received honoraria, research funding, and/or travel/accommodation expenses funding from Bayer, Roche, Amgen, Eli Lilly, PharmaMar, AstraZeneca, and Pfizer. A. E. has received personal fees from Actelion, Agenus, Amgen, Bayer, Bristol Myers Squibb, Catalym, CellDex, Gilead, GlaxoSmithKline, HalioDX, Incyte, IO Biotech, ISA Pharmaceuticals, MedImmune, Merck Sharp \& Dohme, Nektar, Novartis, Pfizer, Polynoma, Regeneron, Sanofi and SkylineDx; and has equity in RiverDx, SkylineDx and Theranovir. E. E. V. is legally responsible for all contracts with pharmaceutical companies, as medical director of the Netherlands Cancer Institute. C. C. is a member of the External Science Panel of AstraZeneca and of Illumina{\textquoteright}s Scientific Advisory Board, and his laboratory has received research grants (administered by the University of Cambridge) from Genentech, Roche, AstraZeneca and Servier. J. T. provides a scientific consultancy role for Array Biopharma, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Genentech, Genmab, Halozyme, Imugene, Inflection Biosciences, Ipsen, Kura Oncology, Lilly, Merck Sharp \& Dohme, Menarini, Merck Serono, Merrimack, Merus, Molecular Partners, Novartis, Peptomyc, Pfizer, Pharmacyclics, ProteoDesign, Rafael Pharmaceuticals, F. Hoffmann La Roche, Sanofi, SeaGen, Seattle Genetics, Servier, Symphogen, Taiho, VCN Biosciences, Biocartis, Foundation Medicine, HalioDX SAS and Roche Diagnostics. J. R. reports research funding from Bayer \& Novartis; clinical research for Spectrum Pharmaceuticals, Tocagen, Symphogen, BioAlta, Pfizer, GenMab, CytomX, KELUN-BIOTECH, Takeda-Millennium, GlaxoSmithKline and Ipsen; is on the scientific advisory board of Novartis, Eli Lilly, Orion Pharmaceuticals, Servier Pharmaceuticals, Peptomyc, Merck Sharp \& Dohme, Kelun Pharmaceuticals/ Klus Pharma, Spectrum Pharmaceuticals, Pfizer, Roche Pharmaceuticals and Ellipses Pharma; and reports research funding for Bayer \& Novartis. J. L. reports research funding from AstraZeneca, Novartis and GE healthcare; and is a co-founder and shareholder of FenoMark Diagnostics.",

year = "2020",

month = jul,

day = "1",

doi = "10.1038/s41591-020-0969-2",

language = "English",

volume = "26",

pages = "992--994",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Research",

number = "7",

}

TY - JOUR

T1 - Support systems to guide clinical decision-making in precision oncology

T2 - The Cancer Core Europe Molecular Tumor Board Portal

AU - Cancer Core Europe consortium

AU - Tamborero, David

AU - Dienstmann, Rodrigo

AU - Rachid, Maan Haj

AU - Boekel, Jorrit

AU - Baird, Richard

AU - Braña, Irene

AU - De Petris, Luigi

AU - Yachnin, Jeffrey

AU - Massard, Christophe

AU - Opdam, Frans L.

AU - Schlenk, Richard

AU - Vernieri, Claudio

AU - Garralda, Elena

AU - Masucci, Michele

AU - Villalobos, Xenia

AU - Chavarria, Elena

AU - Anand, Shubha

AU - Azaro, Analía

AU - Baars, Danny

AU - Bajalica-Lagercrantz, Svetlana

AU - Balmaña, Judith

AU - Bergh, Jonas

AU - Bierkens, Mariska

AU - Blomqvist, Lennart

AU - Doherty, Gary J.

AU - Forest, Arnauld

AU - Fornerone, Valentina

AU - Funingana, Ionut Gabriel

AU - Gabaldi, Paola

AU - Hartman, Johan

AU - Horak, Peter

AU - Karlsson, Claes

AU - Kasanicki, Mary

AU - Kreutzfeldt, Simon

AU - Lewensohn, Rolf

AU - Lindberg, Johan

AU - Lopez, Carlos

AU - Lundqvist, Andreas

AU - Martin-Romano, Patricia

AU - Martin, Jose Ezequiel

AU - Meijer, Gerrit

AU - Muñoz, Susana

AU - Camus, Maud Ngo

AU - Nicotra, Claudio

AU - Nuciforo, Paolo

AU - Oberrauch, Petra

AU - Östling, Päivi

AU - Piris-Giménez, Alejandro

AU - Provenzano, Elena

AU - Eggermont, Alexander

N1 - Funding Information: Orion Pharma and speaker activities for Bristol Myers Squibb; reports travel grants from AstraZeneca and Merck Serono; and is a principal investigator of clinical trials for AstraZeneca, Bristol Myers Squibb, Celgene, Gliknik, GlaxoSmithKline, Janssen, Kura, Merck, Sharp & Dohme, Novartis, Orion Pharma, Pfizer, Shattuck, Northern Biologics, Rakutan Aspirian and Nanobiotics. C. M. reports consultant and/or advisory fees from Amgen, Astellas, Astra Zeneca, Bayer, BeiGene, Bristol Myers Squibb, Celgene, Debiopharm, Genentech, Ipsen, Janssen, Lilly, MedImmune, Merck, Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi, Orion; and is a principal or sub-investigator of clinical trials for Abbvie, Aduro, Agios, Amgen, Argen-x, Astex, AstraZeneca, Aveopharmaceuticals, Bayer, Beigene, Blueprint, Bristol Myers Squibb, Boeringer Ingelheim, Celgene, Chugai, Clovis, Daiichi Sankyo, Debiopharm, Eisai, Eos, Exelixis, Forma, Gamamabs, Genentech, Gortec, GlaxoSmithKline, H3 biomedicine, Incyte, Innate Pharma, Janssen, Kura Oncology, Kyowa, Lilly, Loxo, Lysarc, Lytix Biopharma, Medimmune, Menarini, Merus, Merck, Sharp & Dohme, Nanobiotix, Nektar Therapeutics, Novartis, Octimet, Oncoethix, Oncopeptides, Orion, Pfizer, Pharmamar, Pierre Fabre, Roche, Sanofi, Servier, Sierra Oncology, Taiho, Takeda, Tesaro and Xencor. R. S. reports research funding from Pfizer, AstraZeneca, PharmaMar, Roche and Daiichi Sankyo; speaker honoraria from Pfizer, Daiichi Sankyo and Novartis; and participation in advisory boards at Pfizer, Daiichi Sankyo and Novartis. E. G. reports consultant honoraria from Roche/Genentech, F. Hoffmann La Roche, Ellipses Pharma, Neomed Therapeutics, Boehringer Ingelheim–Janssen Global Services, AstraZeneca, SeaGen, TFS–Alkermes; reports research for Novartis/Roche; is a principal or sub-investigator of clinical trials for Principia Biopharma, Lilly, Novartis Farmacéutica, Genentech, Loxo Oncology, F. Hoffmann La Roche, Symphogen, Merck, Sharp & Dohme de España, Incyte Biosciences International, Pharma Mar, Kura Oncology, Macrogenics, Glycotope, Pierre Fabre Medicament, Cellestia Biotech, Menarini Ricerche Spa, Blueprint Medicines, Beigene Usa, Sierra Oncology and Genmab; reports travel grants from Bristol-Mayers Squibb, Merck Sharp & Dohme, Menarini, Glycotope; and is on the speakers bureau for Bristol-Mayers Squibb, Merck Sharp & Dohme, Roche and ThermoFisher. S. F. reports a consulting or advisory role, having received honoraria, research funding, and/or travel/accommodation expenses funding from Bayer, Roche, Amgen, Eli Lilly, PharmaMar, AstraZeneca, and Pfizer. A. E. has received personal fees from Actelion, Agenus, Amgen, Bayer, Bristol Myers Squibb, Catalym, CellDex, Gilead, GlaxoSmithKline, HalioDX, Incyte, IO Biotech, ISA Pharmaceuticals, MedImmune, Merck Sharp & Dohme, Nektar, Novartis, Pfizer, Polynoma, Regeneron, Sanofi and SkylineDx; and has equity in RiverDx, SkylineDx and Theranovir. E. E. V. is legally responsible for all contracts with pharmaceutical companies, as medical director of the Netherlands Cancer Institute. C. C. is a member of the External Science Panel of AstraZeneca and of Illumina’s Scientific Advisory Board, and his laboratory has received research grants (administered by the University of Cambridge) from Genentech, Roche, AstraZeneca and Servier. J. T. provides a scientific consultancy role for Array Biopharma, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Genentech, Genmab, Halozyme, Imugene, Inflection Biosciences, Ipsen, Kura Oncology, Lilly, Merck Sharp & Dohme, Menarini, Merck Serono, Merrimack, Merus, Molecular Partners, Novartis, Peptomyc, Pfizer, Pharmacyclics, ProteoDesign, Rafael Pharmaceuticals, F. Hoffmann La Roche, Sanofi, SeaGen, Seattle Genetics, Servier, Symphogen, Taiho, VCN Biosciences, Biocartis, Foundation Medicine, HalioDX SAS and Roche Diagnostics. J. R. reports research funding from Bayer & Novartis; clinical research for Spectrum Pharmaceuticals, Tocagen, Symphogen, BioAlta, Pfizer, GenMab, CytomX, KELUN-BIOTECH, Takeda-Millennium, GlaxoSmithKline and Ipsen; is on the scientific advisory board of Novartis, Eli Lilly, Orion Pharmaceuticals, Servier Pharmaceuticals, Peptomyc, Merck Sharp & Dohme, Kelun Pharmaceuticals/ Klus Pharma, Spectrum Pharmaceuticals, Pfizer, Roche Pharmaceuticals and Ellipses Pharma; and reports research funding for Bayer & Novartis. J. L. reports research funding from AstraZeneca, Novartis and GE healthcare; and is a co-founder and shareholder of FenoMark Diagnostics.

PY - 2020/7/1

Y1 - 2020/7/1

UR - https://www.scopus.com/pages/publications/85087559990

U2 - 10.1038/s41591-020-0969-2

DO - 10.1038/s41591-020-0969-2

M3 - Letter

C2 - 32632195

AN - SCOPUS:85087559990

SN - 1078-8956

VL - 26

SP - 992

EP - 994

JO - Nature Medicine

JF - Nature Medicine

IS - 7

ER -